ISPOR 2018
May 19-23, 2018
Baltimore Convention Center
Baltimore, MD, USA
Program
» Search the meeting program and create your personalized schedule
» myISPORBaltimore
(Program subject to change)
Program Wednesday, May 23, 2018
|
IP18: WHEN RESEARCH QUESTIONS COLLIDE: HOW MUCH IS THE UNITED STATES ACTUALLY SPENDING ON DRUGS? |
|
| Moderator: |
Michael Kleinrock, MA, Research Director, IQVIA Institute for Human Data Science, Plymouth Meeting, PA, USA |
| Panelists: |
Sean Keehan, MA, Economist, Office of the Actuary, Centers for Medicare and Medicaid Services, Baltimore, MD, USA Cynthia Cox, MPH, Director, Program for the Study of Health Reform and Private Insurance, Kaiser Family Foundation, Washington, DC, USA Sara Sadownik, MSc, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission, Boston, MA, USA |
| Moderator: |
Kristen Migliaccio-Walle, BS, Director, Global Health Economics & Outcomes Research, Xcenda, LLC, Palm Harbor, FL, USA |
| Panelists: |
Donna Cryer, JD, President and CEO, Global Liver Institute, Washington, DC, USA Daniel A Ollendorf, PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA Robert W Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA |
| W17: DO CUTTING-EDGE ONE-TIME TREATMENTS NEED EQUALLY INNOVATIVE-, OUTCOMES-, OR ANNUITY-BASED PAYMENT MODELS? | |
| Discussion Leaders: |
Mark Chalmers, PhD, Principal & EU Lead, CBPartners, London, UK Andrew Gould, MS, Principal, CBPartners, New York, NY, USA Maximilian Hunt, BSc, Principal, CBPartners, New York, NY, USA Omar Ali, BSc, DipClinPharm, MRPharmS, ACPP, Pharmacy Director, QIPP Adviser Commissioning Payer Network & former ERG Cost Impact Modelling, NICE, London, UK |
| W18: OPEN SOURCE SOFTWARE FOR BUILDING HEALTH ECONOMIC MODELS | |
| Discussion Leaders: |
Joseph F Levy, BS, Postdoctoral Fellow, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA Fernando Alarid-Escudero, PhD, Post-Doctoral Associate, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA Erik J Dasbach, PhD, Executive Director, Outcomes Research, Merck & Co. Inc., Kenilworth, NJ, USA |
Professor, The University of Texas College of Pharmacy, Austin, TX, USA
CP1
8:30 AM - 8:45 AMAN ANALYTICAL FRAMEWORK FOR ECONOMIC EVALUATION OF INTERVENTIONS WITH EFFECTS ON MULTIPLE OUTCOMES, COSTS FALLING ON DIFFERENT BUDGETS, AND INVOLVING MORE THAN ONE DECISION MAKER
Griffin S1, Walker S2, Sculpher M1, Asaria M21University of York, York, UK, 2University of York, Heslington, York, UK
CP2
8:45 AM - 9:00 AMGRAPHICAL PROBABILISTIC MODELS FOR RISK PREDICTION AND DECISION MAKING USING REAL-WORLD DATA: A DEVELOPING TOOL FOR THE ERA OF PRECISION MEDICINE
Arora P1, Boyne DJ2, Druzdzel MJ31Lighthouse Outcomes, Toronto, ON, Canada, 2University of Calgary, Calgary, ON, Canada, 3University of Pittsburgh, Pittsburgh, PA, USA
CP3
9:00 AM - 9:15 AMASSESSMENT-TIME BIAS: STATISTICAL APPROACHES TO ADJUSTING FOR BETWEEN-TRIAL DIFFERENCES IN THE SCHEDULE OF ASSESSMENT FOR DISEASE PROGRESSION IN IMMUNO-ONCOLOGY TRIALS
Kapetanakis V1, Schlichting M2, Stevens JW3, Prawitz T1, Kearney M4, Phatak H5, Benedict A6, Bharmal M41Evidera, London, UK, 2Global Biostatistics and Epidemiology, Merck KGaA, Darmstadt, Germany, 3Reader in Decision Science, University of Sheffield, Sheffield, UK, 4Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 5EMD Serono, Rockland, MA, USA, 6Evidera, Budapest, Hungary
CP4
9:15 AM - 9:30 AMBUDGET IMPACT ANALYSIS WITH SIMULTANEOUS MULTIPLE MARKET ENTRANTS: STATIC VERSUS DYNAMIC BASELINE MARKET SHARES
O'Day K, Meyer KXcenda, Palm Harbor, FL, USA
Associate Professor, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, USA
HE1
8:30 AM - 8:45 AMEFFECT OF A PROVIDER-FOCUSED ASTHMA CARE QUALITY IMPROVEMENT PROGRAM ON PATIENT-LEVEL ASTHMA-RELATED HEALTH CARE COSTS
Rojanasarot S, Carlson AM, St. Peter WL, Schommer JCCollege of Pharmacy, University of Minnesota, Minneapolis, MN, USA
HE2
8:45 AM - 9:00 AMHEALTH CARE COSTS IN DIABETES: THE ROLE OF COMORBIDITY TYPE
Lin P1, Pope E1, Zhou FL21Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Sanofi, Bridgewater, NJ, USA
HE3
9:00 AM - 9:15 AMA TALE OF TWO UNIVERSAL HEALTH INSURANCE SCHEMES IN ONE COUNTRY: HORIZONTAL INEQUALITY OF GOVERNMENT MEDICAL AND PHARMACEUTICAL BENEFITS FOR AUSTRALIAN CHILDREN
Huang L, Clarke P, Dalziel KThe University of Melbourne, Melbourne, Australia
HE4
9:15 AM - 9:30 AMREAL-WORLD ANALYSIS OF TREATMENT PATTERNS AND LONG-TERM EFFECTIVENESS AMONG PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS OF LUNG ORIGIN (LUNG NET): A MULTICENTER STUDY
Dasari A1, Bergsland EK2, Benson AB3, Cai B4, Huynh L5, Totev T5, Shea J5, Duh MS5, Neary MP4, Kulke MH61University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Analysis Group, Inc., Boston, MA, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
ISPOR Student Network Advisor and Vice President, Celgene Corporation, Summit, NJ, USA
PhRMA Health Outcomes Advisory Committee, Independent Research Consultant, New Hope, PA, USA
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Senior Director, Benefit-risk Assessment, Department of Epidemiology, Janssen Research & Development, Titusville, NJ, USA
Global Head of Clinical Outcomes, Sanofi, Guildford, Surrey, UK
Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA
| Moderator: |
Mike Ciarametaro, MBA, Vice President, National Pharmaceutical Council, Washington, DC, USA |
| Panelists: |
Ilene L. Hollin, PhD, MPH, Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics, Washington, DC, USA David Wamble, MS, MBA, Director, Health Economics, RTI Health Solutions, Durham, NC, USA Josh Seidman, PhD, MHS, Senior Vice President, Avalere, Washington, DC, USA |
|
IP21: IS ARTIFICIAL INTELLIGENCE THE NEXT BIG THING IN HEALTHCARE DECISION MAKING? |
|
| Moderator: |
Santiago Ernesto Herran, MD, Market Access Head, Bayer Andina, Bogota, Colombia |
| Panelists: |
Rafael Alfonso Cristancho, MD, MSc, PhD, Senior Director, Value Evidence Outcomes, R&D, GlaxoSmithKline, Collegeville, PA, USA Juan-David Rueda, MD, MS, Doctoral Candidate, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA Carrie Savage Bennette, PhD, MPH, Senior Methodologist, Flatiron, NY, NY, USA |
| W19: MEDICAL DEVICE REAL-WORLD EVIDENCE FOR BEGINNERS: A PRIMER | |
| Discussion Leaders: |
Stephen S Johnston, MA, Director, Johnson & Johnson, Inc., New Brunswick, NJ, USA Joshua Gagne, PharmD, ScD, Associate Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics; Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA Frank R. Ernst, PharmD, MS, Executive Director, Real-World Evidence, CTI Clinical Trial and Consulting Services, Covington, KY, USA Abhishek S Chitnis, MPharm, PhD, Associate Director, Epidemiology, Medical Devices, Real World Analytics and Research, Johnson & Johnson, New Brunswick, NJ, USA |
| W20: FIXING THE TOWER OF BABEL: ESTABLISHING A COMMON METRIC FOR PATIENT-REPORTED OUTCOME MEASURES | |
| Discussion Leaders: |
Jakob B. Bjorner, MD, PhD, CSO, Optum Patient Insights, Johnston, RI, USA Benjamin D. Schalet, PhD, Research Assistant Professor of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Felix Fischer, PhD, Researcher, Department for Psychosomatic Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany Ian Kudel, PhD, Senior Scientist, Optum Patient Insights, Johnston, RI, USA |
| W21: PRINCIPLES OF EFFECTIVE MACHINE LEARNING APPLICATIONS IN REAL WORLD EVIDENCE | |
| Discussion Leaders: |
Andrew Cox, PhD, Research Scientist, Data Analytics, Evidera, London, UK Sreeram Ramagopalan, Ph.D, Director, Center for Observational Research and Data Sciences (CORDS), Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK Gorana Capkun-Niggli, PhD, Head of HEOR Innovation, Novartis Pharma AG, Basel, Switzerland David J. Vanness, PhD, Associate Professor, Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA |
Professor of Health Economics and Dean of ScHARR, University of Sheffield, Sheffield, UK
PP1
1:45 PM - 2:00 PMPATIENT PREFERENCES FOR HEALTH STATES FOLLOWING ALTERNATIVE MANAGEMENT OPTIONS FOR DUCTAL CARCINOMA IN SITU
Campbell BM1, Yang J2, Gonzalez JM2, Reed SD2, Havrilesky L3, Johnson FR2, Hwang ES31Duke University School of Medicine, Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke Cancer Insitute, Durham, NC, USA
PP2
2:00 PM - 2:15 PMCHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L
Craig BM1, Rand K21University of South Florida, and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA, 2University of Oslo, Oslo, Norway
PP3
2:15 PM - 2:30 PMESTIMATING THE HEALTH STATE UTILITY OF PATIENTS WITH HER2– GBRCA+ METASTATIC BREAST CANCER TREATED WITH OLAPARIB OR CHEMOTHERAPY VIA A MAPPING ANALYSIS OF EORTC QLQ-C30 DATA COLLECTED IN THE OLYMPIAD CLINICAL TRIAL
Robson M1, Hettle R2, Degboe A3, Saunders O4, Cain T4, Kilvert H4, Johnson H41Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2AstraZeneca, Cambridge, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Bresmed Ltd, Sheffield, UK
PP4
2:30 PM - 2:45 PMCONSUMER PREFERENCES FOR PRECISION MEDICINE TECHNOLOGIES: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT
Regier DA1, Veenstra DL2, Basu A3, Saha J2, Carlson JJ31BC Cancer/University of British Columbia, Vancouver, BC, Canada, 2Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA
| Moderator: |
Tyler J. O'Neill, DVM, MSc, PhD, Scientist, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA |
| Panelists: |
Michael S. Waters, PhD, SHIELD Team Lead; CDRH RWE Tactical Team – Diagnostics, Office of in vitro Diagnostics and Radiologic Health (OIR), Food and Drug Administration (FDA), Silver Spring, MD, USA Brad Spring, BS, Vice President, Regulatory Affairs, BD Life Sciences, Sparks, MD, USA Asif Jan, PhD, Lead, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA |
| Moderator: |
Helen Kitchen, MSc, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK |
| Panelists: |
Kathryn Lasch, PhD, Executive Director, Patient Reported Outcomes, Pharmerit International, Newton, MA, USA Helen Doll, PhD, Strategic Lead, Quantitative Science, Clinical Outcomes Solutions, Folkestone, UK Katy Benjamin, PhD, Director, HEOR - Patient Reported Outcomes, Abbvie Inc, Chicago, IL, USA |
| W22: THE MEDIUM IS THE MESSAGE: USING INTERACTIVE GRAPHICS TO EFFECTIVELY COMMUNICATE HEALTH ECONOMICS AND OUTCOMES RESEARCH FINDINGS | |
| Discussion Leaders: |
Shelagh M Szabo, MSc, Principal and Scientific Director, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada Ross Tsuyuki, MSc PharmD, Professor, University of Alberta, Edmonton, AB, Canada Andrew Lloyd, PhD, Director, Acaster Lloyd Consulting Ltd., London, UK Bonnie M Donato, PhD, Senior Director, Global Health Outcomes, Alexion Pharmaceuticals, Inc, New Haven, CT, USA |
| W23: ESTIMATING THE COST OF ADVERSE EVENTS IN ECONOMIC MODELS: A DISCUSSION OF REAL-WORLD DATA VERSUS TREATMENT GUIDELINES BASED METHODOLOGIES | |
| Discussion Leaders: |
William Wong, PharmD, MS, Sr. Health Economist, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA Martin Cloutier, MSc, Manager, Analysis Group, Inc., Montreal, QC, Canada Josh J. Carlson, MPH, PhD, Associate Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA |
Professor and Vice-Chair for Academic Affairs PHSR, University of Maryland School of Pharmacy, Baltimore, MD, USA
IN1
3:00 PM - 3:15 PMUSING ELECTRONIC HEALTH RECORDS TO EXAMINE HPV VACCINE INITIATION AND COMPLETION RATES
Yu J, Buikema AR, Togun AOptum, Eden Prairie, MN, USA
IN2
3:15 PM - 3:30 PMLONG-TERM HEALTH BENEFIT OF IBALIZUMAB IN THE TREATMENT OF ADULTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION
Brogan AJ1, Talbird SE2, Davis AE2, La EM2, Miao Z3, Lewis S41RTI Health Solutions, Didsbury, Manchester, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Theratechnologies Inc., Montréal, QC, Canada, 4TaiMed Biologics, Irvine, CA, USA
IN3
3:30 PM - 3:45 PMINCIDENCE OF HEPATOCELLULAR CARCINOMA AND EXTRAHEPATIC CANCERS AMONG HCV-INFECTED PATIENTS IN THE ERA OF DIRECT-ACTING ANTIVIRALS
Wang W1, Lo Re III V2, Xiao H1, Brown J1, Yi G1, Park H11University of Florida, Gainesville, FL, USA, 2University of Pennsylvania, Philadelphia, PA, USA
IN4
3:45 PM - 4:00 PMESTIMATING THE CURRENT COST OF ENDOSCOPIC SINUS SURGERY IN THE US – A CLAIMS-BASED APPROACH
Velez FF1, Sacks H1, Messina J1, Kozma CM2, Malone D3, Mahmoud R11OptiNose US, Inc., Yardley, PA, USA, 2CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 3University of Arizona, Tucson, AZ, USA
Associate Professor, Temple University College of Public Health, Philadelphia, PA, USA
ND1
3:00 PM - 3:15 PMUSE OF DISEASE MODIFYING AGENTS IN PATIENTS WITH MULTIPLE SCLEROSIS: ANALYSIS OF TEN YEARS OF NATIONAL DATA
Earla JR1, Paranjpe R1, Kachru N2, Aparasu RR11University of Houston, Houston, TX, USA, 2Gilead Sciences Inc., Foster City, CA, USA
ND2
3:15 PM - 3:30 PMHOW PRESCRIPTION DRUG COST FOR DISEASE MODIFYING THERAPY (DMT) IMPACTS OVERALL HEALTH CARE SPENDING AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS
Kim Y1, Krause TM1, Freeman L21The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA, 2The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA
ND3
3:30 PM - 3:45 PMPRODUCTIVITY LOSSES AMONG PATIENTS WITH MIGRAINE: AN ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA
Porter JK1, Di Tanna GL1, Lipton RB2, Sapra S3, Villa G11Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of Medicine, Bronx, NY, USA, 3Amgen Inc, Thousand Oaks, CA, USA
ND4
3:45 PM - 4:00 PMCOST-UTILITY ANALYSIS COMPARING ABOBOTULINUMTOXINA WITH ONABOTULINUMTOXINA FOR THE TREATMENT OF PEDIATRIC LOWER LIMB SPASTICITY
Johnston KM1, Hansen RN2, Cheung A1, Liovas A3, Armstrong A3, Danchenko N4, Bains S5, Dinet J4, Sullivan SD21Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2University of Washington, Seattle, WA, USA, 3Ipsen Biopharmaceuticals Canada, Mississauga, ON, Canada, 4Ipsen Global, Boulogne-Billancourt, France, 5Ipsen US, Basking Ridge, NJ, USA